middle.news
Neuren Confirms DAYBUE Sales Could Surge to US$700m by 2028
9:20am on Monday 19th of January, 2026 AEDT
•
Healthcare
Read Story
Neuren Confirms DAYBUE Sales Could Surge to US$700m by 2028
9:20am on Monday 19th of January, 2026 AEDT
Key Points
Neuren relies solely on royalties and milestones from Acadia’s DAYBUE sales
Acadia projects DAYBUE net sales to hit ~US$700 million globally by 2028
Neuren confirms compliance with ASX continuous disclosure rules
Projection assumes European approval expected in Q1 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE